Cannabidiol Combination Platform: A path to safer treatment

Cannabidiol (CBD) is the main non-psychotropic component of the glandular hairs of Cannabis sativa. It displays a plethora of actions including anticonvulsive, sedative, hypnotic, antipsychotic, anti-inflammatory and neuroprotective properties. It is well established that CBD produces its biological effects without exerting significant intrinsic activity upon cannabinoid receptors. For this reason, CBD lacks the unwanted psychotropic effects characteristic of marijuana derivatives. Hence, making it the most suitable candidate for further evaluation for the treatment of number of CNS disorders. Oral Cannabidiol has low bioavailability (~6%) requiring a high dose for efficacy. High doses cause dose-related elevations of liver transaminases (alanine aminotransferase [ALT] and/or aspartate aminotransferase [AST]. Hepatoxicity due to high doses of CBD remains a significant limitation of its development and use for newer therapies. MR-601 is a unique combination technology for administration of Cannabidiol at lower dosage levels, while still achieving the desired efficacy, improving bioavailability, and potentially reducing the hepatoxicity related to higher dosage levels.